{"id":"insulin-lispro-lm","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin lispro LM (also known as Humalog Mix) is a fixed-ratio mixture of insulin lispro (a rapid-acting insulin analog) and insulin lispro protamine suspension (intermediate-acting). The rapid-acting component addresses postprandial (after-meal) blood glucose spikes, while the intermediate-acting component provides basal insulin coverage between meals and overnight. This dual-action formulation simplifies insulin therapy by combining two insulin types in a single injection.","oneSentence":"Insulin lispro LM is a premixed insulin formulation that combines rapid-acting insulin lispro with intermediate-acting insulin to provide both mealtime and basal glucose control.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:16.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01175824","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":478},{"nctId":"NCT00279201","phase":"PHASE4","title":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2","enrollment":2091},{"nctId":"NCT00393705","phase":"PHASE4","title":"Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":302},{"nctId":"NCT00420095","phase":"PHASE4","title":"A Study for Patients With Diabetes Mellitus (IOPA)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-01","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low Mix","Humalog"],"phase":"marketed","status":"active","brandName":"insulin lispro LM","genericName":"insulin lispro LM","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin lispro LM is a premixed insulin formulation that combines rapid-acting insulin lispro with intermediate-acting insulin to provide both mealtime and basal glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}